ENDRA Life Sciences Inc. Receives Nasdaq Delisting Notice Due to Failure to Meet Minimum Stockholders’ Equity Requirement

Key Points for Investors

• ENDRA Life Sciences Inc. (Nasdaq: NDRA) has received a formal delisting notice from The Nasdaq Stock Market LLC due to non-compliance with the minimum stockholders’ equity requirement of \$2.5 million.
• The company’s audited financials as of December 31, 2025, reported stockholders’ equity of \$2,260,120, which is below the required threshold.
• ENDRA intends to request a hearing before the Nasdaq Hearings Panel to appeal the determination, which will temporarily stay any delisting action.
• There is no assurance that ENDRA will regain compliance or remain listed on Nasdaq.

Detailed Analysis

ENDRA Life Sciences Inc., a medical technology company listed on Nasdaq under the ticker symbol NDRA, announced that it has received a letter from Nasdaq’s Listing Qualifications Staff stating that, based on the company’s recent Annual Report on Form 10-K, its stockholders’ equity has fallen below the minimum requirement set forth in Nasdaq Listing Rule 5550(b)(1). This rule mandates that companies maintain a minimum of \$2,500,000 in stockholders’ equity to remain listed on the exchange.

The company’s annual filing for the period ended December 31, 2025, disclosed stockholders’ equity of \$2,260,120. This shortfall triggered the current notification and follows a series of prior communications with Nasdaq. Previously, ENDRA had been notified of non-compliance and was granted an extension to regain compliance, which it initially achieved in November 2025. However, the latest audited results showed a return to non-compliance.

Shareholder Impact and Price-Sensitive Information

• Delisting Risk: If ENDRA is unable to regain compliance or its appeal is unsuccessful, the company’s shares could be delisted from Nasdaq. Delisting typically results in reduced liquidity, a lower profile among investors, and potential downward pressure on the share price.
• Next Steps: ENDRA has stated its intention to request a hearing before the Nasdaq Hearings Panel. This request will stay any further Nasdaq action, including delisting, pending the outcome of the hearing and any extensions the Panel may grant.
• Uncertainty Remains: The company is currently evaluating all available options to resolve the deficiency and regain compliance but explicitly notes there can be no assurance of success. Failure to regain compliance or an unsuccessful appeal could result in ENDRA’s removal from Nasdaq, which is a material and price-sensitive event.

Management’s Forward-Looking Statement

The company cautions shareholders and investors that statements regarding its ability to regain compliance, the outcome of any hearing, and other future events are “forward-looking statements.” These statements are based on current expectations and assumptions and involve risks and uncertainties. Actual results may differ, and ENDRA does not undertake any obligation to update forward-looking statements except as required by law.

Conclusion

The Nasdaq delisting notice represents a significant development for ENDRA Life Sciences Inc. and its shareholders. The outcome of the upcoming hearing and the company’s efforts to regain compliance will have a material impact on the company’s trading status and potentially its valuation. Investors should monitor further announcements closely.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The information herein is based on publicly available filings as of the date indicated and may be subject to change.

View ENDRA Life Sciences Inc. Historical chart here